News Related to AAVantgarde Bio

Related coverage linked through entity extraction aliases.

Ray Therapeutics Receives EMA PRIME Designation for RTx-015 Gene Therapy in Retinitis Pigmentosa

May 01, 2026

Ray Therapeutics received EMA PRIME designation for its RTx-015 optogenetic gene therapy for retinitis pigmentosa, following recent FDA RMAT status. The company also appointed Michael Murtagh as Chief Regulatory Officer to support global development.

AAV Gene Therapy Advances for Neovascular AMD and Inherited Retinal Diseases

Feb 13, 2026

AAV-based gene therapy offers sustained intraocular delivery of anti-angiogenic agents with a single treatment for neovascular AMD, with leading clinical candidates including RGX-314, ADVM-022, 4D-150, and NG101.